NYSE:ARMK • US03852U1060
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARAMARK (ARMK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-17 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-12 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-11 | Stifel | Maintains | Buy -> Buy |
| 2025-12-17 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-19 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-11-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-01 | UBS | Maintains | Buy -> Buy |
| 2025-08-06 | UBS | Maintains | Buy -> Buy |
| 2025-08-06 | Baird | Upgrade | Neutral -> Outperform |
| 2025-06-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-07 | UBS | Maintains | Buy -> Buy |
| 2025-05-07 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-11 | UBS | Maintains | Buy -> Buy |
| 2025-02-24 | Citigroup | Reiterate | Buy |
| 2025-02-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-12-12 | Baird | Maintains | Neutral -> Neutral |
| 2024-12-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-12 | Stifel | Maintains | Buy -> Buy |
| 2024-11-12 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-12 | Baird | Maintains | Neutral -> Neutral |
| 2024-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-10-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.083B -1.49% | 17.401B 8.19% | 18.506B 6.35% | 20.171B 9.00% | 21.395B 6.07% | 22.587B 5.57% | 23.951B 6.04% | 25.286B 5.57% | 27.69B 9.51% | |
| EBITDA YoY % growth | 1.077B -5.84% | 1.177B 9.34% | 1.268B 7.73% | 1.563B 23.25% | 1.723B 10.24% | 1.839B 6.73% | 1.917B 4.24% | 2.019B 5.32% | 2.178B 7.88% | |
| EBIT YoY % growth | 666.728M 9.12% | 741.61M 11.23% | 791.846M 6.77% | 1.131B 42.83% | 1.265B 11.85% | 1.374B 8.62% | 1.489B 8.37% | 1.603B 7.66% | 1.727B 7.74% | |
| Operating Margin | 4.15% | 4.26% | 4.28% | 5.61% | 5.91% | 6.08% | 6.22% | 6.34% | 6.24% | |
| EPS YoY % growth | 1.69 43.22% | 1.55 -8.28% | 1.82 17.42% | 2.25 23.73% | 2.64 17.31% | 3.03 14.80% | 3.23 6.61% | 3.56 10.09% | 3.90 9.46% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.48 42.07% | 0.49 21.68% | 0.75 31.48% | 0.62 21.23% | 0.56 15.13% | 0.58 20.03% | 0.84 11.86% | 0.66 7.24% | 0.61 9.12% | 0.65 10.87% | 0.83 -0.84% |
| Revenue Q2Q % growth | 4.845B 13.22% | 4.981B 7.66% | 5.387B 6.71% | 5.096B 5.47% | 5.074B 4.73% | 5.297B 6.34% | 5.691B 5.64% | 5.407B 6.10% | 5.36B 5.64% | 5.589B 5.51% | 5.821B 2.28% |
| EBITDA Q2Q % growth | 363.31M -10.17% | 363.16M -32.08% | 456.63M -34.22% | 409.71M 19.27% | 388.21M 6.85% | 406.96M 12.06% | 496.38M 8.71% | 431.7M 5.37% | 414.2M 6.69% | 430.81M 5.86% | 499.31M 0.59% |
| EBIT Q2Q % growth | 255.96M 46.96% | 254.61M 39.45% | 350.37M 60.85% | 308.49M 41.80% | 282.69M 10.44% | 296.6M 16.49% | 374.61M 6.92% | 322.91M 4.67% | 303.31M 7.29% | 317.21M 6.95% | 384.6M 2.67% |
All data in USD
21 analysts have analysed ARMK and the average price target is 47.45 USD. This implies a price increase of 15.61% is expected in the next year compared to the current price of 41.04.
ARAMARK (ARMK) will report earnings on 2026-05-04, before the market open.
The consensus EPS estimate for the next earnings of ARAMARK (ARMK) is 0.48 USD and the consensus revenue estimate is 4.84B USD.
The number of analysts covering ARAMARK (ARMK) is 21.